WFSBP Programme 2015

WFSBP 2015

Scientific Programme

Tuesday, 16 June 2015

P-10-010

The prevalence of bipolar spectrum disorder in elderly

patients with recurrent depression

Young-Eun Jung, Republic of Korea

P-10-011

Libidinal increase induced by memantine

Jaehyun Kim, Republic of Korea

Y. Paik

P-10-012

Safety of quetiapine for treatment of geriatric psychosis

Gorana Sulejmanpasic-Arslanagic, Bosnia and Herzegovina

S. Fisekovic, A. Kucukalic, S. Ler

P-10-013

Improving wellness and quality of life of mental health

consumers: An eight-year naturalistic evaluation of the

CHU de Québec-IUSMQ Mieux-Être Wellness Program

Christian Shriqui, Canada

I. Lachance, A. Aubin, S. Bonneville, I. Paradis

P-10-014

Comparison of depressive symptoms of the Hamilton

Depression Rating Scale between elderly and non-elderly

outpatients with major depressive disorder

Ikki Yoo, Republic of Korea

P-11

Poster Presentation

12:45–14:15

Muses Foyer

Pharmacological and Brain Stimulation Therapies

Chair:

Elias Angelopoulos, Greece

Co-Chair: Styliani Kaliora, Greece

P-11-001

Deficient assessment and reporting of adverse events in

antidepressant clinical trials

Rajnish Mago, USA

J. Chaves, S. Kaur

P-11-002

Detect neural dynamics across acute, chronic and discon-

tinuation SSRI administration

Shahak Yariv, Israel

R. Perets, Y. Shohat, R. Paz

P-11-003

Involvement of 5-HT1A receptors of the dorsal hippocam-

pus in the anxiogenic effect caused by acute antidepressant

administration in rats

Helio Zangrossi Junior, Brazil

A. B. Sant’ana do Nascimento, H. H. Vilela-Costa, T. de Andrade

P-11-004

Vortioxetine: A meta-analysis of 12 short-term, randomized,

placebo-controlled clinical trials for the treatment of major

depressive disorder

Chi-Un Pae, Republic of Korea

C. Han, A. Serretti

P-11-005

Smoothing spline regression as a modern tool for the anal-

ysis of observational data–moderate depression under

hypericum extract STW3-VI (900 mg daily) compared to

selective serotonin reuptake inhibitors in routine outpatient

treatment

Juergen Mueller, Germany

C. Kolb, O. Kelber, C. Theurer

P-11-006

St John’s wort: What is the key for the bioavailability of

a phytomedicine active in mild to moderate depression?

Christiane Kolb, Germany

V. Butterweck, O. Kelber, S. Verjee, H. Abdel-Aziz

P-11-007

Brain state-dependent abnormal LFP activity in the auditory

cortex of a schizophrenia mouse model

Kazutoshi Nakazawa, USA

K. Nakao

P-11-008

Gender differences regarding prolactin levels, ASEX and

PANSS scales in schizophrenic patients

Christina Kalkavoura, Greece

I. Michopoulos, P. Arvanitakis, P. Theodoropoulou, K. Dimo-

poulou, E. Tzebelikos

P-11-009

Metabolic syndrome risk of antipsychotics: One year fol-

low-up study

Ayse Nur Inci Kenar, Turkey

E. Hanci, K. Saricay

P-11-010

Does aripiprazole augmentation reduce prolactine levels

and relieves related symptoms in women patients treated

with amisulpride?

Sarpe Marcel, Romania

P. Dan, P. Ruxandra, L. Maria

P-11-011

Therapeutic dose range of valproate-induced hyperam-

monemic encephalopathy: A case report

Chul Eung Kim, Republic of Korea

S. Maeng, J. H. Rho